ZacksMay 6, 2026, 12:00 AMnasdaq
Sight Sciences (SGHT) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Sight Sciences (SGHT) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Open articleZacksMay 6, 2026, 12:00 AMnasdaq
Sight Sciences, Inc. (SGHT) Reports Q1 Loss, Beats Revenue Estimates
Sight Sciences (SGHT) delivered earnings and revenue surprises of +14.30% and +6.06%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Open articleThe Motley FoolMay 6, 2026, 12:00 AMnasdaq
Sight Sciences (SGHT) Q1 2026 Earnings Transcript
@media (max-width: 768px) {
.image-container {
width: 100% !important;
float: none !important;
margin: 0 0 1rem 0 !important;
}
}
Image source: The Mo
Open articleRTTNewsMar 5, 2026, 12:00 AMnasdaq
Sight Sciences Q4 Net Loss Narrows; Expects 6-14% Revenue Growth In FY26
(RTTNews) - Sight Sciences, Inc. (SGHT), an eyecare technology company, reported financial results for the fourth quarter and full year 2025. In addition, it provided guidance for the full year 2026.
Open articleThe Motley FoolMar 4, 2026, 12:00 AMnasdaq
Sight Sciences (SGHT) Q4 2025 Earnings Transcript
@media (max-width: 768px) {
.image-container {
width: 100% !important;
float: none !important;
margin: 0 0 1rem 0 !important;
}
}
Image source: The Mo
Open articleZacksMar 4, 2026, 12:00 AMnasdaq
Sight Sciences (SGHT) Reports Q4 Earnings: What Key Metrics Have to Say
The headline numbers for Sight Sciences (SGHT) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Open articleZacksMar 4, 2026, 12:00 AMnasdaq
Sight Sciences, Inc. (SGHT) Reports Q4 Loss, Beats Revenue Estimates
Sight Sciences (SGHT) delivered earnings and revenue surprises of +44.83% and +0.34%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Open articleZacksFeb 25, 2026, 12:00 AMnasdaq
RxSight, Inc. (RXST) Reports Q4 Loss, Beats Revenue Estimates
RxSight (RXST) delivered earnings and revenue surprises of +87.14% and +0.02%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Open articleZacksFeb 25, 2026, 12:00 AMnasdaq
Sight Sciences, Inc. (SGHT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Sight Sciences (SGHT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Open articleZacksFeb 19, 2026, 12:00 AMnasdaq
Pulse Biosciences, Inc (PLSE) Reports Q4 Loss, Beats Revenue Estimates
Pulse Biosciences (PLSE) delivered earnings and revenue surprises of +18.75% and +5.60%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Open articleZacksJan 21, 2026, 12:00 AMnasdaq
908 Devices (MASS) Moves 19.2% Higher: Will This Strength Last?
908 Devices (MASS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Open articleFintelJan 14, 2026, 12:00 AMnasdaq
Sight Sciences (SGHT) Price Target Increased by 19.11% to 9.54
The average one-year price target for Sight Sciences (NasdaqGS:SGHT) has been revised to $9.54 / share. This is an increase of 19.11% from the prior estimate of $8.01 dated December 18, 2025. The price target is an average of many targets provided by analysts.
Open article